CO6680624A2 - Tratamiento de queloide - Google Patents

Tratamiento de queloide

Info

Publication number
CO6680624A2
CO6680624A2 CO13015329A CO13015329A CO6680624A2 CO 6680624 A2 CO6680624 A2 CO 6680624A2 CO 13015329 A CO13015329 A CO 13015329A CO 13015329 A CO13015329 A CO 13015329A CO 6680624 A2 CO6680624 A2 CO 6680624A2
Authority
CO
Colombia
Prior art keywords
treating
keloid
scar keloid
scar
treatment
Prior art date
Application number
CO13015329A
Other languages
English (en)
Inventor
Adebola O E Obayan
Sanjeev Singh
Brenda Collen Joyce Yuzdepski
Original Assignee
Adetherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adetherapeutics filed Critical Adetherapeutics
Publication of CO6680624A2 publication Critical patent/CO6680624A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona un método de tratar o prevenir o tratar profilácticamente un queloide cicatricial. En una modalidad preferida se provee un método de tratar o prevenir o tratar profilácticamente un queloide cicatricial, método que comprende administrar tópicamente a un sitio de formación de queloide cicatricial o formación potencial de queloide cicatricial una cantidad efectiva de L-alanil-L-glutamina en un organogel. La invención es útil en el tratamiento de queloide cicatricial.
CO13015329A 2010-06-28 2013-01-28 Tratamiento de queloide CO6680624A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35905310P 2010-06-28 2010-06-28

Publications (1)

Publication Number Publication Date
CO6680624A2 true CO6680624A2 (es) 2013-05-31

Family

ID=45401271

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13015329A CO6680624A2 (es) 2010-06-28 2013-01-28 Tratamiento de queloide

Country Status (14)

Country Link
US (1) US20140005116A1 (es)
EP (1) EP2585090A4 (es)
JP (1) JP2013533867A (es)
KR (1) KR20130089174A (es)
CN (1) CN103002903B (es)
AU (1) AU2011274224A1 (es)
BR (1) BR112012033349A2 (es)
CA (1) CA2804413A1 (es)
CO (1) CO6680624A2 (es)
HK (1) HK1183626A1 (es)
MX (1) MX2013000107A (es)
RU (1) RU2578426C2 (es)
WO (1) WO2012000113A1 (es)
ZA (1) ZA201209759B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000545B2 (en) 2013-03-15 2021-05-11 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US10398733B2 (en) 2013-03-15 2019-09-03 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
FR3004353B1 (fr) * 2013-04-10 2015-05-15 Fabre Pierre Dermo Cosmetique Association synergique de l'alanine-glutamine, l'acide hyaluronique et un extrait d'avoine, et son utilisation dans une composition destinee a la cicatrisation et la reparation des lesions cutanees
KR101800788B1 (ko) * 2017-03-31 2017-11-27 박영오 켈로이드 흉터 개선용 화장료 조성물
US10500318B1 (en) * 2018-07-03 2019-12-10 Temple Therapeutics BV Dosing regimens for treating hypoxia-associated tissue damage
US11193184B2 (en) 2019-02-22 2021-12-07 Cda Research Group, Inc. System for use in producing a metal ion suspension and process of using same
CN114767590B (zh) * 2022-04-20 2024-03-15 上海交通大学医学院附属第九人民医院 一种祛疤祛痘印美容液及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5740409A (en) * 1980-08-22 1982-03-06 Mitsui Toatsu Chem Inc Remedy for disease caused by extraordinary propagation of collagen
US6149925A (en) * 1998-11-05 2000-11-21 Color Access, Inc. Topical compositions for enhancing glutathione production
WO2001014527A1 (en) * 1999-08-23 2001-03-01 Organogenesis Inc. Skin care compositions and treatments
JP2004532230A (ja) * 2001-04-30 2004-10-21 アラクノーバ・セラピューティックス・リミテッド Ppar−ガンマアクチベーターを使用する瘢痕化および関連状態の処置
US20030105025A1 (en) * 2001-10-31 2003-06-05 Fortuna Haviv Tri-and tetrapeptides having antiangiogenic activity
RU2234963C2 (ru) * 2002-09-16 2004-08-27 Сибирский государственный медицинский университет Способ лечения гипертрофических и келоидных кожных рубцов
CN103623390A (zh) * 2003-09-12 2014-03-12 科罗拉多州大学评议会 用于治疗损伤的谷氨酰胺
RU2275216C1 (ru) * 2004-12-08 2006-04-27 Елена Григорьевна Арий Способ профилактики формирования патологических кожных рубцов
DK1940439T3 (da) * 2005-08-11 2011-02-14 Univ Saskatchewan Nedsættelse af postoperativ adhæsionsdannelse med intraperitoneal glutamin
EP1947938A4 (en) * 2005-11-02 2009-07-01 Cpex Pharmaceuticals Inc MACROCYCLIC FORMULATIONS FOR TRANSMEMBRANE DRUG DELIVERY
CN100372522C (zh) * 2005-12-02 2008-03-05 何秋莎 护肤品
CA2578647A1 (en) * 2007-02-15 2008-08-15 University Of Saskatchewan Reducing post-operative adhesion formation with intraperitoneal glutamine

Also Published As

Publication number Publication date
JP2013533867A (ja) 2013-08-29
EP2585090A1 (en) 2013-05-01
AU2011274224A8 (en) 2014-09-18
CA2804413A1 (en) 2012-01-05
MX2013000107A (es) 2013-06-03
AU2011274224A1 (en) 2013-01-17
CN103002903B (zh) 2015-04-22
US20140005116A1 (en) 2014-01-02
EP2585090A4 (en) 2014-01-15
WO2012000113A1 (en) 2012-01-05
RU2578426C2 (ru) 2016-03-27
CN103002903A (zh) 2013-03-27
KR20130089174A (ko) 2013-08-09
ZA201209759B (en) 2014-03-26
HK1183626A1 (en) 2014-02-14
RU2013103507A (ru) 2014-08-10
BR112012033349A2 (pt) 2016-10-11

Similar Documents

Publication Publication Date Title
CO6680624A2 (es) Tratamiento de queloide
UA110338C2 (en) Chemical compounds
CO6761389A2 (es) Inhibidores de nampt y rock
ECSP13012420A (es) Derivados de tetrahidro-pirido-pirimidina
IN2014CN04634A (es)
UA110813C2 (uk) Лікування ліподистрофії
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
MX2014005440A (es) Inhibidores de nicotinamida adenina dinucleotido difosfato oxidasa-4 y uso de los mismos.
EA201300688A1 (ru) Новая форма введения ингибитора энкефалиназы
UY34466A (es) Proceso para estabilizar contenido bacteriano de treparaciones minerales acuosas que comprenden carbbonatos de calcio.
CR20120551A (es) Mètodo para el tratamiento de un lìquido, en particular un aceite mineral
ITMI20120370A1 (it) Miscela antimicrobica e rivestimento per supportare la guarigione di ferite, che ha un effetto antimicrobico.
AR089320A1 (es) Cepa de lactobacillus mucosae
EA201201296A1 (ru) Способы лечения диабетических язв стопы
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.
BR112013029672A2 (pt) uso de inibição da catepsina k para o tratamento e/ou profilaxia da hipertensão pulmonar e/ou insuficiência cardíaca
MX348397B (es) Uso de extractos de filipendula para el tratamiento y profilaxis de dolor crónico.
WO2011083482A3 (en) Method for treatment of psoriasis
GT201400038A (es) Composiciones y métodos para tratar el cáncer usando el inhibidor de p13kbeta y el inhibidor de la vía de mapk, incluidos los inhibidores de mek y raf
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
MX2015011567A (es) Halogeno-pirazoles como inhibidores de trombina.
EA201491581A1 (ru) Везикулярные композиции
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
UA115052C2 (uk) Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор
CR20150159A (es) Derivados oxazolidinona 3,4-disustituidos y su uso como inhibidores de potasio calcio activado